Abstract: FR-PO126
Procalcitonin (PCT) Levels in Septic and Nonseptic Participants with AKI before and during Continuous Kidney Replacement Therapy (CKRT)
Session Information
- AKI: Diagnosis and Outcomes
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Acute Kidney Injury
- 102 AKI: Clinical, Outcomes, and Trials
Authors
- Foulon, North, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Okamura, Kayo, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- He, Zhibin, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Kennis, Matt Robert, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Colbert, James F., University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
- Faubel, Sarah, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Background
PCT is a 14.5 kDa protein and biomarker of bacterial infection. PCT is increased in ESKD and plasma levels decline after hemodialysis, suggesting clearance by the kidney and KRT. Herein, we measured plasma PCT in septic and non-septic patients with AKI and tested the hypothesis that PCT would be increased in AKI without sepsis and cleared by CKRT.
Methods
Plasma and effluent PCT were determined in septic and non-septic subjects with AKI that were selected from a prospective observational cohort of 126 patients who received CKRT at a single center. Plasma was collected prior to CKRT initiation, and plasma and effluent were collected on days 1, 2, and 3 of CKRT. Inclusion criteria for sepsis subjects were: 1) AKI without CKD, and 2) clinical diagnosis of sepsis and 2/2 positive blood cultures. Inclusion criteria for non-septic subjects were: 1) AKI without CKD, and 2) no clinical diagnosis of sepsis and no positive blood cultures. The sepsis cohort contained 9 patients, and the non-septic cohort contained 27 patients. 9 healthy control (HC) subjects with neither kidney disease nor sepsis were also studied.
Results
Plasma PCT was significantly increased in non-septic subjects with AKI vs. healthy controls. Plasma PCT was significantly increased in septic AKI subjects compared to non-septic (Figure 1). No significant difference existed in serum PCT of septic or non-septic AKI patients after 3 days of CKRT compared to pre-CKRT samples (Figure 2A and 2B). The average sieving coefficient for procalcitonin was 0.27 (Figure 3A). The average procalcitonin clearance was 7.05 L on day 1, 12.84 L on day 2, and 10.94 on day 3 of CKRT (Figure 3B).
Conclusion
Plasma PCT is significantly increased in non-septic patients with AKI suggesting that acute kidney function decline affects plasma PCT levels. Although some level of PCT clearance by CKRT was observed, changes in serum PCT were unpredictable during CKRT in both septic and non-septic patients. Our data suggest PCT results should be interpreted cautiously in patients with AKI prior to and during CKRT.